Video

Experts Provide Insight on Aspects of Cancer Care That Are Not as Widespread in Community Practice

Author(s):

OncLive Staff

In Partnership With:

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

OncLive interviewed experts at the State of the Science Summits™ in October 2019 on what they wish more people knew in community practice that is not yet widespread.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Arvind N. Dasari, MD, MS
Charles E. Geyer, Jr., MD
Sattva S. Neelapu, MD
Ann S. LaCasce, MD, MMSc
George Yaghmour, MD, and Rachel Elizabeth Rau, MD, on factors for frontline treatment in adult and pediatric acute lymphoblastic leukemia.
Alvaro Alencar, MD
Rory Shallis, MD
Dimitrios Nasioudis, MD
Patrick I. Borgen, MD, chair, Department of Surgery, Maimonides Medical Center; head, Maimonides Breast Center, Maimonides Cancer Center
Patrick I. Borgen, MD, chair, Department of Surgery, Maimonides Medical Center; head, Maimonides Breast Center, Maimonides Cancer Center
Related Content
Sheela Rao, MBBS, MD, FRCP
January 7th 2025

Retifanlimab Emerges as Potential New SOC in Advanced SCAC

MedNews Week
January 1st 2025

DESTINY-Breast06 Data Demonstrate the Role of T-DXd in HER2-Low and -Ultralow Breast Cancer: With Chandler Park, MD; and Guiseppe Curigliano, MD, PhD

catalin – stock.adobe.com
January 7th 2025

Sunvozertinib Under FDA Priority Review for NSCLC With EGFR Exon 20 Insertion Mutations

James J. Harding, MD, director, Early Drug Development, Memorial Sloan Kettering Cancer Center
December 30th 2024

FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer

Armin Ghobadi, MD
January 7th 2025

WT-7 Shows Acceptable Safety Profile in Relapsed/Refractory T-ALL/LBL

Ropeginterferon Alfa-2b in Essential Thrombocytopenia | Image Credit: © Tatiana Shepeleva - stock.adobe.com
Published: January 6th 2025 | Updated: January 8th 2025

Second-Line Ropeginterferon Alfa-2b Boosts Responses in Essential Thrombocythemia